Alpha Cognition Inc Alpha Cognition Inc

Alpha Cognition Inc

ACOG

Classificação em ações #20413
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Preço da ação
$8.13
Última sincronização: 2026-10-16
Valor de mercado
$126.27M
Variação (1 dia)
-3.79%
Variação (1 ano)
61.63%
País
US
Negociar Alpha Cognition Inc (ACOG)

Categoria

Healthcare
EPS de Alpha Cognition Inc (ACOG)
EPS em June 2026 TTM: $-0.40
De acordo com os últimos relatórios financeiros e o preço das ações da Alpha Cognition Inc, o EPS atual da empresa (TTM) é $-0.40. No final de 2022, a empresa teve um EPS de $-0.18, uma diminuição em relação a ao EPS de 2021, que foi de $-0.37.
Histórico de EPS da Alpha Cognition Inc de 2018 até 2026
EPS no final de cada ano
Ano EPS Alterar
2026 (TTM) $-0.40 166.67%
2023 $-0.15 -16.67%
2022 $-0.18 -51.35%
2021 $-0.37 -61.46%
2020 $-0.96 357.14%
2019 $-0.21 672.06%
2018 $-0.03 0.00%
EPS de empresas semelhantes ou concorrentes
Empresa EPS Diferença de EPS País
$17.32 -4,430.00%
US
$-7.98 1,895.00%
US
$-5.29 1,222.50%
AU
- -
CH
$27.74 -7,035.00%
NL